Skip to Main Content

Paper Details

Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
EJHaem
7
2022
-T cell, BCMA, Selinexor, anti-B-cell maturation antigen, anti-BCMA, antigen receptor, chimeric antigen receptor, chimeric antigen receptor-T cell, multiple myeloma, patients, selinexor
Author NameAffiliation
John T SchillerHematological Malignancy/Stem Cell Transplant Program University of California - Los Angeles David Geffen School of Medicine Los Angeles California USA.
Sumit MadanBanner MD Anderson Cancer Center Gilbert Arizona USA.
  • 1 - 2

Datasets

Release 1.2